PPARδ agonists have been shown beneficial in models of metabolic disorders in primates and may thus possess therapeutic potential in hyperlipidemia, atherosclerosis, obesity, and diabetes [93,94]. This evidence concerns the gene PPARD and Other metabolic disease.